Key facts
- Eolo Pharma’s last known valuation is $18.0M (Sep 2022).
- It has raised $7.7M; the latest was Later Stage VC ($170K) in Mar 2025.
- Notable investors include Cites Startups, Ficus Capital, Securitas Biosciences Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Eolo Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Eolo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eolo Pharma
Developer of a pharmacological platform designed to treat obesity and its related chronic diseases through targeted small-molecule therapies. The company offers a unique library of novel chemical entities, including thermogenic compounds like MVD1 that address metabolic and neuroinflammatory conditions, enabling healthcare providers to manage obesity, type 2 diabetes, and neurodegenerative disorders with more precise and effective treatments.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2017
- Employees
- 8
- Website
- eolo-pharma.com/
- Ownership
- Privately Held (backing)
Eolo Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eolo Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eolo Pharma in its N-PORT filings yet. We sweep new filings monthly.